☆ 4.5 Article

Risk reduction of severe outcomes in vaccinated COVID-19 cases: an analysis of surveillance data from Estonia, Ireland, Luxembourg and Slovakia, January to November 2021

EUROSURVEILLANCE (2022)

Related references

Note: Only part of the references are listed.
Article Infectious Diseases

Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021

Margaux M. Mesle et al.

Summary: Between December 2019 and November 2021, COVID-19 vaccination in 33 countries in the World Health Organization European Region saved approximately 51% of expected deaths in the population aged 60 years and older. The impact of vaccination varied by country, with the largest effect seen in countries where implementation was carried out early.

EUROSURVEILLANCE (2021)

Add to Collection
Review Infectious Diseases

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021

Thomas Harder et al.

Summary: Research shows that COVID-19 vaccines are effective in preventing various degrees of infection, with efficacy rates of 63.1%, 75.7%, and 90.9% against asymptomatic infection, symptomatic infection, and hospitalization, respectively. Compared to the Alpha variant, the efficacy against mild outcomes is slightly reduced by 10-20%, but remains fully maintained against severe COVID-19.

EUROSURVEILLANCE (2021)

Add to Collection
Article Infectious Diseases

Initial assessment of the COVID-19 vaccination's impact on case numbers, hospitalisations and deaths in people aged 80 years and older, 15 EU/EEA countries, December 2020 to May 2021

Nathalie Nicolay et al.

Summary: Prioritizing elderly individuals in COVID-19 vaccination campaigns can significantly reduce severe outcomes in this age group, particularly when vaccination uptake reaches 80% or higher.

EUROSURVEILLANCE (2021)

Add to Collection
Article Multidisciplinary Sciences

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

Barak Mizrahi et al.

Summary: The study indicates preliminary evidence of waning vaccine effectiveness of BNT162b2 among all age groups above 16, with a higher incidence of infection in those vaccinated earlier in 2021. Further investigation into long-term protection against different strains is warranted.

NATURE COMMUNICATIONS (2021)

Add to Collection
Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

Add to Collection
Article Infectious Diseases

First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020

Gianfranco Spiteri et al.

EUROSURVEILLANCE (2020)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.